PACS Group (PACS) saw its stock price surge by 38.80% in pre-market trading on Thursday, following the release of its impressive third-quarter financial results and optimistic outlook for the full year 2025. The healthcare operations company's performance significantly exceeded market expectations, triggering a wave of investor enthusiasm that began in after-hours trading on Wednesday.

The company reported robust third-quarter figures, with quarterly revenue reaching $1.34 billion, marking a substantial 31.0% increase compared to the same period last year. This figure surpassed analyst estimates of $975.647 million by an impressive 37.86%. While earnings per share of $0.32 slightly missed the consensus estimate of $0.33, it still represented a remarkable 220% improvement from the previous year's $0.10 per share.

Investors were particularly encouraged by PACS Group's forward-looking projections. The company anticipates full-year 2025 revenue to be between $5.25 billion and $5.35 billion, with adjusted EBITDA expected in the range of $480 million to $490 million. This positive outlook, coupled with the company's announcement of completing the restatement of previous financial statements and becoming current with SEC filing obligations, has bolstered confidence in PACS Group's financial transparency and growth potential.

Furthermore, PACS Group's expanding portfolio, which now includes 320 healthcare operations across 17 states, with ownership of 51 facilities and purchase options on an additional 59 facilities, signals strong growth prospects in the post-acute healthcare sector. The company's strategy of pursuing growth through a combination of leasing, acquisitions, and evaluating opportunities in both high-performing and underperforming operations appears to be resonating well with investors, contributing to the significant stock price surge.